Contrave vs Qsymia: Comparing the Two Oral Non-GLP-1 Weight-Loss Pills

A decision-focused look at two FDA-approved oral pills, how they work, what the trials show, and who each one fits.

If you have decided against GLP-1 injections, or you simply cannot get one right now, you have not run out of options. Two oral pills, Contrave and Qsymia, were built for exactly this situation: chronic weight management in adults who need medical help beyond diet and activity alone. They are taken by mouth, they have years of prescribing history, and they work in ways that have nothing to do with the GLP-1 hormone pathway. They are also quite different from each other. This is a plain comparison of the two, meant to help you have a better conversation with a clinician, not to steer you toward one before anyone has looked at your history.

Two pills, two very different engines

Contrave and Qsymia are both combination products, which means each one pairs two older medicines into a single formulation. That is roughly where the similarity ends.

Contrave combines naltrexone and bupropion in an extended-release tablet. Bupropion nudges dopamine and norepinephrine signaling, and naltrexone blocks opioid receptors. Together they act on the brain's appetite center in the hypothalamus and on the reward and craving circuitry in the mesolimbic system. The label is honest that the exact mechanism is not fully established. In everyday terms, people often describe it as taking some of the pull out of food, the mental tug toward the pantry at 9 pm. It was FDA-approved in September 2014 for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition.

Qsymia combines phentermine and topiramate in a once-daily morning capsule. Phentermine is a sympathomimetic amine, a stimulant that suppresses appetite. Topiramate, borrowed from the seizure and migraine world, tends to increase the feeling of fullness. It reached the market a bit earlier, in 2012, for the same weight-management indication. Where Contrave leans on cravings, Qsymia leans on hunger and satiety.

What the trials actually show

Here is the part where honesty matters most. In its pivotal COR trials at 56 weeks, Contrave produced roughly 5 to 6 percent average weight loss on the maintenance dose, compared with about 1 percent on placebo. Around half of treated patients lost at least 5 percent of their starting weight. Qsymia generally does more: in the CONQUER and EQUIP trials, average loss ran about 8 percent on the recommended dose and closer to 10 to 11 percent on the top dose, with roughly 70 percent of top-dose patients losing at least 5 percent.

Those are averages from studies, and individual results vary a great deal. Some people respond well, some barely move, and the only way to learn your own response is to try it under supervision. It also helps to set expectations against the newer injectables. Semaglutide 2.4 mg averaged about 15 percent in its trial, and tirzepatide 15 mg about 21 percent. Neither oral pill is in that range. If you want to understand that gap in detail, see our comparisons of semaglutide versus Contrave and semaglutide versus Qsymia. The point is not that Contrave and Qsymia are weak. It is that they should be chosen for the right reasons, not sold as equal to something they are not.

Who Contrave may suit, and who should not take it

Contrave may fit a person whose eating is driven by cravings, reward, or grazing, especially someone who would rather avoid a stimulant. But it carries real limits, and one of them is a boxed warning.

Because Contrave contains bupropion, an antidepressant, it carries a boxed warning for suicidal thoughts and behaviors. Anyone taking it should be watched for new or worsening depression, agitation, or changes in mood and behavior, and should stay in close contact with the prescriber. Contrave is not approved to treat depression, anxiety, any other psychiatric condition, or smoking cessation, and it should not be used for those reasons.

It is contraindicated in several situations, including:

• uncontrolled high blood pressure
• a seizure disorder or any history of seizures
• bulimia or anorexia nervosa
• chronic opioid use, or being in acute opioid withdrawal
• abruptly stopping alcohol, benzodiazepines, barbiturates, or antiseizure medicines
• use of any other bupropion-containing product
• taking an MAOI now or within the past 14 days
• pregnancy

Blood pressure and heart rate need monitoring while a person is on it, since bupropion can nudge both upward.

Who Qsymia may suit, and who should not take it

Qsymia may fit a person whose main struggle is appetite and portion size, and who has no reason to avoid a stimulant. Its efficacy is a genuine draw. But it comes with the most logistical strings of the two, largely because of one ingredient.

Topiramate is teratogenic. Pregnancy-registry data have linked first-trimester exposure to oral clefts in roughly 1.4 percent of exposed infants, versus about 0.3 percent without exposure, along with a higher chance of a small-for-gestational-age baby. For that reason Qsymia is dispensed only through a restricted program, the Qsymia REMS, using certified pharmacies. Anyone who could become pregnant is advised to have a negative pregnancy test before starting and monthly during treatment, and to use effective contraception throughout. This is not a detail to gloss over.

Qsymia is contraindicated in pregnancy, glaucoma, and hyperthyroidism, and with an MAOI taken now or within 14 days. Its other warnings include:

• sudden vision changes from acute myopia or angle-closure glaucoma
• a metabolic acidosis that calls for bicarbonate monitoring
• trouble with attention, memory, or finding words
• tingling in the hands and feet, reported in about 20 percent at the top dose
• a small rise in resting heart rate
• mood changes or suicidal thoughts, a signal seen across antiseizure drugs

Two more practical notes. Phentermine is a DEA Schedule IV controlled substance, which shapes how it is prescribed and refilled. And topiramate should never be stopped abruptly; it is tapered down under a clinician's guidance to avoid seizure risk. None of that is a reason to fear the drug, but it is a reason to take the monitoring seriously.

The 12-week checkpoint both share

One thing the two pills have in common is a built-in honesty check. For both, the labeling sets a point around 12 weeks on the maintenance dose to ask a simple question: is this working for you? With Contrave, if you have not lost at least 5 percent of your starting weight by then, the guidance is to stop, because continuing is unlikely to pay off. Qsymia has its own staged version of the same idea, reassessed at each step. The lesson for you is that neither drug is meant to be taken indefinitely on faith. If the scale and your clinician agree it is not helping, that is useful information, not a personal failure.

Cost, monitoring, and the cash-pay picture

Both are branded medications, and coverage for weight-loss drugs is uneven, so many people end up paying out of pocket. When you compare true cost, look past the sticker price to the logistics. Qsymia adds the REMS program, certified-pharmacy dispensing, controlled-substance refill rules, and monthly pregnancy testing for those who need it. Contrave has no scheduling paperwork, but it does need blood-pressure and mood monitoring. A cash-pay telehealth practice can build either kind of follow-up into a visit, and knowing which set of check-ins fits your life is part of the decision.

One clarification that matters: neither Contrave nor Qsymia is a compounded medication. They are FDA-approved branded pills made to a fixed formula. That is a separate category from compounded semaglutide or tirzepatide, which are not FDA-approved and not brand-identical, and whose results vary by individual. It is worth keeping those buckets apart when you weigh choices, so you are comparing like with like.

Where these pills sit next to other options

If you landed here because injections were off the table, it helps to see the whole menu. Contrave and Qsymia are useful oral tools with modest, real average results. GLP-1 and GIP therapies tend to produce larger average loss but come with their own considerations and eligibility rules, which we cover in who qualifies for a GLP-1. At the far end, for people with more weight to lose or medical urgency, our piece on GLP-1 versus bariatric surgery lays out how medication and procedures compare. There is no single best pill, only the one that fits your body, your history, and the trade-offs you are willing to make.

The honest bottom line

Contrave and Qsymia are both reasonable, FDA-approved oral choices for someone who has ruled out or cannot get GLP-1 injections. Contrave works on cravings and carries a boxed warning around mood, along with blood-pressure and seizure cautions. Qsymia works on appetite, tends to produce more weight loss, and asks more of you in monitoring, above all strict pregnancy prevention. Neither matches the newer injectables on the scale, and neither should be started without a clinician reviewing your full history. Dr. Anjmun Sharma, MD can walk through which contraindications apply to you and what monitoring a safe trial would involve. That conversation, not a headline, is where the right answer lives.

Contrave and Qsymia are registered trademarks of their respective manufacturers; this clinic is not affiliated with, endorsed by, or sponsored by them. This article is educational and is not medical advice.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.